The objective of the Innovation Scorecard is to support appropriate access to NICE approved products (medicines, devices and diagnostics), by giving health and care commissioners and professionals information they can use to identify and act on unwarranted variation in patient access to these treatments.
The Scorecard does this by transparently providing access to data, which can be used alongside a range of other data sources (including patient population outcomes) to measure progress in access to NICE approved products within local areas or at a national level. It is not intended to be used for performance management.
The Innovation Health and Wealth Strategy set out plans to support development and adoption of innovation in the NHS. The National Institute for Health and Care Excellence (NICE) technology appraisal process assesses the clinical and cost effectiveness of new and existing medicines and treatments, and provides guidance on their use by the NHS.
There is no central collection of data which can directly support the assessment of uptake of NICE recommendations, nor is data on the number of patients treated available.
Therefore this is an experimental publication, which makes use of data currently available from a range of sources, both from the NHS and the commercial sector.